The moment of truth is arriving for AstraZeneca’s anti-infectives unit. For more than a year now, the pharma giant has been quietly shopping a deal, seeking an investor willing to take control of the assets, while allowing AstraZeneca to keep a substantial stake for itself, FierceBiotech has learned. Now, industry insiders are buzzing that the company is coming down to the wire on a final decision–and that throughout the negotiations, staffers have been steadily fleeing the once-sizable operation.

…read more

Source: AstraZeneca struggles to spin out anti-infectives division, coming down to the wire


0 No comments